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Ziel: Die Prognose für Patienten mit hochgradigem serösem Ovarialkarzinom (HGSOC) ist 
schlecht. Derzeit gibt es keine definierten Biomarker, die zwischen einer guten und einer 
schlechten Prognose unterscheiden könnten. In dieser Studie soll untersucht werden, ob es 
Unterschiede bei den Angiogenese-Biomarkern zwischen Langzeitüberlebenden und denen 
mit schlechter Prognose gibt, wobei Tumorproben aus einer großen Kohorte von 
Langzeitüberlebenden und passenden Kontrollen verwendet werden. 
 
Methoden: Aus der Tumor Bank Ovarian Cancer wurden Tumorproben von 62 
"Langzeitüberlebenden" und 62 passenden Kontrollen identifiziert. Alle Patienten wurden als 
HGSOC in fortgeschrittenen Stadien diagnostiziert [Federation International of Gynecology 
and Obstetrics (FIGO) Stadium III-IV]. Patienten, bei denen nach einer primären 
platinbasierten Chemotherapie für mindestens 5 Jahre (5+ Jahre) kein Rezidiv auftrat, 
wurden als „Langzeitüberlebende“ definiert, und Patienten, bei denen das erste Rezidiv 
zwischen 6 Monaten und 3 Jahren auftrat, wurden für die Kontrollen ausgewählt. Langzeit- 
und Kontrollkohorten wurden nach Alter und postoperativen Tumorresten verglichen. Eine 
pathologische Untersuchung wurde durchgeführt, um die hochgradige seröse Histologie 
nachzuweisen. Immunhistochemie wurde an Tumorproben durchgeführt, um die Expression 
des vaskulären endothelialen Wachstumsfaktors (VEGF) A und des VEGF-Rezeptors 2 
(VEGFR2) zu bestimmen. Der Chi-Quadrat-Test oder der Fisher-Test wurde verwendet, um 
den Unterschied zwischen Langzeit- und Kontrollgruppen bei den Biomarkern festzustellen. 
 
 
Ergebnisse: Die VEGFA-Expression korrelierte signifikant mit der VEGFR2-Expression (p 
<0,0001, Spearman-Koeffizient 0,347). Obwohl die VEGFA-Expression nicht mit dem 
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progressionsfreien 5-Jahres-Überleben (PFS) (p = 0,075) zusammenhängt, wurde eine 
Überexpression von VEGFR2 bei Langzeitüberlebenden häufiger beobachtet (77,4%, 48/62) 
als bei Kontrollpersonen (51,6%, 30) / 62, p = 0,001). Der Unterschied in VEGFR2 blieb nach 
Anpassung des FIGO-Stadiums und der VEGFA-Expression signifikant (p = 0,005). In der 
gesamten Kohorte der analysierten Patienten wurde das höchste Expressionsniveau von 
VEGFR2 in einer Untergruppe von Patienten mit PFS über 10 Jahre (10+ Jahre) beobachtet 
(p = 0,001). 
 
Schlussfolgerungen: Unsere Studie zeigte eine signifikante Korrelation zwischen 
VEGFR2-Überexpression und 5+ Jahre PFS bei HGSOC-Patienten, unabhängig von Alter, 
















Objective: The prognosis for high-grade serous ovarian cancer (HGSOC) patients is poor. 
There are no defined biomarkers to identify between good and poor prognosis at the present. 
This study is to analyze if there are differences in angiogenesis biomarkers between long-
term survivors and poor survivors, using tumor samples from a large cohort of long-term 
survivors and matched controls. 
 
Methods: Tumor samples of 62 “long-term survivors” and 62 matched controls were 
identified from the Tumor Bank Ovarian Cancer. All patients were diagnosed as HGSOC in 
advanced stages [Federation International of Gynecology and Obstetrics (FIGO) stage III-
IV]. Patients with no relapse for at least 5 years (5+ years) after primary platinum-based 
chemotherapy were defined as “long-term survivor”, and patients who had the first relapse 
occurred between 6 months and 3 years were selected for controls. Long-term and control 
cohorts were matched by age and post-surgical tumor residuals. A pathological review has 
been performed in order to prove the high-grade serous histology. Immunohistochemistry 
was performed on tumor samples to determine the expressions of vascular endothelial 
growth factor (VEGF) A and VEGF receptor 2 (VEGFR2). Chi-square test or Fisher’s test 
were used to access the difference in biomarkers between long-term and control groups.  
 
Results: VEGFA expression was found to be significantly correlated with VEGFR2 
expression (p<0.0001, Spearman coefficient 0.347). Although VEGFA expression was not 
related to 5+ years progression-free survival (PFS) (p=0.075), VEGFR2 overexpression was 
seen more frequently in long-term survivors (77.4%, 48/62) than in controls (51.6%, 30/62, 
p=0.001). The difference in VEGFR2 remained significant after adjusting FIGO stage and 
VEGFA expression (p=0.005). Within the whole cohort of analyzed patients, the highest 
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expression level of VEGFR2 was seen in subgroup of patients with PFS longer than 10 years 
(10+ years) (p=0.001). 
 
Conclusion: Our study showed a significant correlation between VEGFR2 overexpression 
and 5+ year PFS in HGSOC patients, independent of age, FIGO stage, residual tumor mass 




















Almost 70-80% of ovarian-cancer-associated death caused by high-grade serous ovarian 
cancer (HGSOC) [1-3]. Although the knowledge of this distinct subtype has been improved 
in past 10 years, the clinical outcome remains poor. The introduction of a taxane and 
platinum-combination chemotherapy has dramatically improved the outcomes 20 years ago. 
Recent phase III clinical trial also proved Olaparibmaintenance treatment significantly 
extended PFS for 13.6 months in BRCA1/2 mutated and platinum-sensitive patients with 
relapsed ovarian cancer, compared with placebo. However, comparing with other 
gynecological malignancies, the long-term survival for HGSOC has only been modestly 
improved, despite all the refinements to surgery and chemotherapy regimens [1] [4]. 
 
Treatment resistance is a crucial factor for the high mortality associated with HGSOC.  
Despite 80% of the patients will benefit from primary cytoreduction and respond well to 
platinum-based chemotherapy, almost all of them will experience multiple recurrences and 
eventually die from a disease that is resistant to platinum chemotherapy [1]. The 
mechanisms of recurrence are diverse in individuals, including the activation of AKT 
signaling, the loss of BRCA1 methylation, reversion of germline mutations in BRCA1/2, a 
shift to a higher stromal content and overexpression of the drug transporter ABCB1[1]. 
Particularly, some patients with established risk factors such as older age, advanced FIGO 
stage, serous histology type and tumor residual still achieved long-term survival after 
completion of chemotherapy. A recent clinical study analyzed 3582 women with epithelial 
ovarian cancer (EOC) to demonstrate that, nearly one-third of 10+ year survivors was initially 
diagnosed at advanced stages, including high-grade serous cancer [5]. Thus, a better 
understanding of particular characters of HGSOC long-term survivors is important to 




In this context, exploring biomarkers to characterize the long-term survivors after platinum 
therapy is urgently needed, in order to find more precise therapy to improve poor outcomes. 
Besides, including long-term survivors into standard treatment regimens may result in 
patients’ overtreatment, whereas into clinical trials may lead to selection-biases and 
subsequently unreliable results.  
 
Angiogenesis process forms new blood vessels to provide nutrients and oxygen for ovarian 
tumors to grow [6-8]. This process is considered to be mainly regulated through the vascular 
endothelial growth factor (VEGF) A and VEGF receptor 2 (VEGFA/VEGFR2) signaling 
pathway [9]. Several studies showed that ovarian cancer is a highly vascularized tumor with 
high levels of VEGF, which usually has been correlated with advanced stages and poor 
clinical outcome [10]. Bevacizumab, the first anti-VEGF therapy approved in OC, has been 
confirmed to improve the PFS without effect on overall survival. However, long-term 
survivors were rarely included in most studies on anti-VEGF/VEGFR therapies in primary 
OC, due to the mean follow-up time being less than 5 years. Thus, angiogenesis 
characteristics of HGSOC patients with very good prognosis are still unclear.  
 
This study aimed to investigate the correlation between VEGFA/VEGFR2 expressions and 






Methods and materials  
 
Sample collection 
In total of 124 patients with primary advanced HGSOC (FIGO stage III-IV) were selected, 
including 62 “long-term survivors” and 62 controls. “Long-term survivors” were patients 
without relapse of the disease within 5 years since the completion of the primary 
chemotherapy (PFS 5+ years). Controls were defined as primary HGSOC patients in whom 
the disease recurred within 6 months to 3 years after the primary chemotherapy (PFS 0.5-3 
years). The two cohorts were 1:1 matched by age at first diagnosis (up to 5 years younger 
or older) and macroscopic tumor residual after initial surgery (no residual vs. with residual).  
 
The 124 patients were all treated from 1985 to 2013 in five European high-volume 
Gynecologic Oncology Centers: Charité Medical University of Berlin, Germany; University-
Medical-Center Hamburg-Eppendorf, Germany; Medical University of Innsbruck, Austria; 
University Hospital Leuven, Belgium; University of Medicine and Pharmacy Iuliu Hatieganu 
Cluj-Napoca, Romania. Their tumor-tissue samples were collected from the Tumor Bank 
Ovarian Cancer Consortium (TOC-consortium, www.toc-network.de). All patients underwent 
cytoreduction and platinum-based chemotherapy following the standard procedure [21]. 
Staging was performed and defined in accordance with the FIGO-criteria for ovarian cancer 
(1987) [22]. Tissue samples of ovarian cancer and patients’ clinical data and follow-up 
information were prospectively collected during the primary cytoreduction within the TOC 
consortium. The diagnosis of HGSOC was confirmed by central histopathological review, 
which was also used to ensure the tissue quality and tumor content. Tumor grading was re-
evaluated according to World Health Organization (WHO) pathological classification (2014).  
Tumor samples for the long-term group were retrieved from all 5 centers of TOC-consortium, 
while the samples in control were only available in Charité Medical University of Berlin. 
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The inclusion criteria were: 1) diagnosis of primary HGSOC, FIGO stage III-IV; 2) platinum-
free survival > 6 months. 3) availability of formalin-fixed, paraffin-embedded ovarian cancer 
tissue samples 4) available clinico-pathological and follow-up information. Patients without 
chemotherapy-naïve tumor tissue for immunohistochemistry were all excluded. 
 
PFS was defined as time interval from the end of first chemotherapy to first recurrence of 
disease. Overall survival (OS) was defined as time interval between diagnosis and patients’ 
death or loss of follow-up. Response to treatment and diagnosis of recurrence was 
determined according to CA125 and imagistic or clinical evidence of relapse. 
 
The study protocol was approved by each local Ethics Committees (Charité 2004-000034, 
Innsbruck AN2015-0237 354/4.7, Hamburg EK200313, Leuven MML1022, Cluj 39). The 
informed consents were given and signed by patients before the surgery and sample 




Hematoxylin and eosin were used to stain sections of chemotherapy naïve ovarian 
carcinoma tissues. A trained pathologist (SD) marked representative tumor areas for tissue 
microarrays (TMAs). Consecutively TMAs were constructed as previously described [24]. 
Per tumor 4 tissue cores of 1.5 mm diameter were used and transferred into a recipient 
paraffin block. Slides were firstly deparaffinated and rehydrated in a series of descending 
alcoholic concentration.  
 
Rabbit polyclonal antibodies directed against the VEGFA or VEGFR2 (Abcam, Cambridge, 
United Kingdom) were purchased for detecting VEGFA and VEGFR2 on tissue samples. For 
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antigen retrieval, slides were boiled in a pressure cooker for 5 minutes in 0.01 M sodium 
citrate buffer at pH 9.0 and then put in TBS-buffer for the same time. After blocking the 
endogenous peroxidase, slides were incubated with the primary antibody, diluted 1:250 for 
VEGFA and 1:500 for VEGFR2 in antibody diluents solution (Zytomed Systems, Berlin, 
Germany) for 30 minutes at room temperature. A Dako Real Detection System (Dako, 
Glostrup, Denmark) was used for visualization, according to a standard protocol provided by 
the manufacturer using DAB+ Chromogen. Counterstaining was carried out with Haemalaun 
(Dr Hollborn, Leipzig, Germany). Afterwards the tissue was dehydrated and cover-slipped 
with Vitroclud (Medizintechnik Langenbrinck, Emmerdingen, Germany).  
 
One experienced pathologist (ETT) and one trained medical student (JG) assessed the 
immunohistochemical expressions for the two bio-markers. These two persons finished the 
evaluation separately without knowing any information regarding patient’s characteristics 
and outcome. When they had different results on the same sample, a multi-headed 
microscope was used to confirm the expression level for both biomarkers. A semi-
quantitative immunoreactivity score (IRS) was applied for calculating the immunoreactivity 
of VEGFA and VEGFR2, as published in previous studies [11, 16, 17, 25]. The IRS (range 
0-12) was obtained by multiplying the scores of staining intensities (range 0-3) and staining 
proportions (range 0-4).  The intensities scores were: 0, negative; 1, weak; 2, moderate; 3, 
strong. And for proportions, scores were calculated as: 0, no cells stained; 1, <10% of cells 
stained; 2, 11-50% of cells stained; 3, 51-80% of cells stained; 4, >80% of cells stained. 
Because no established cut-offs for VEGFA/VEGFR2 expression exists, a logistic regression 
model was then performed with different IRS to conclude a cutoff to dichotomize the 
expressions for VEGFA or VEGFR2. As a consequence, a IRS of 0-6 was defined as “low 





IBM SPSS Statistics 22.0 (SPSS, Inc., Chicago, IL) was used for statistical analyses. 
Categorical variables were presented as frequency with percentage. Continuous variables 
were summarized by means and standard deviations, or median and inter quartile range 
(IQR) where appropriate. The Shapiro-Wilk test was used to the normal distribution for 
continuous variables. When continuous variables were normally distributed, a Student t test 
would be used to examine the intra-group differences. When continuous variables were non-
normally distributed, a Mann-Whitney U test would be performed instead. Difference 
between categorical variables were analyzed by Chi-square test or Fisher’s exact where 
appropriate.  Correlation test (Spearman coefficient, 2-tailed) were performed to analyze 
the correlation between expressions of VEGFA and VEGFR2. Multivariable-logistic 
regression model was used to evaluate the independent impact of VEGFA and VEGFR2. A 


















Patients’ clinico-pathological information are presented in Table 1. No patients had 
experienced anti-VEGF/VEGFR therapy. There was no difference in FIGO stage between 
long-term and control patients (Table 1, Figure 1).  
 
Expressions of VEGFA and VEGFR2 
Stained VEGFA and VEGFR2 proteins were showed to be localized in the cytoplasm (Figure 
2, a-b, e-f). For long-term group and control, the IRS distributions of both biomarkers were 
presented (Figure 2, c, d, g and h). VEGFR2 expression was significantly correlated with 
VEGFA expression (p>0.0001, Spearman coefficient 0.347). VEGFR2 overexpression 
(VEGFR2high) was most frequently seen in long-term groups (77.4%, 48/62) than in the 
control (51.6%, 30/62, p=0.001), even after adjusting FIGO stage and VEGFA expression in 
multivariate analysis (p=0.005, Figure 3b, Table 2). Although more samples (49/62,79.0%) 
in long-term group were evaluated as VEGFA overexpression (VEGFAhigh) than in control 
(40/62, 64.5%), the difference was not statistically significant (p=0.073, Figure 3a, Table 2). 
In addition, overexpression of both two markers were also more frequent in the long-term 
survivors (62.9% 39/62) than in control (42.0%, 26/62, p=0.003, Figure 3c).  
 
VEGFA/VEGFR2 expressions of with-residual and no-residual patients 
We investigated VEGFA and VEGFR2 expressions in patients with (n=28) or without residual 
(n=96). Among both with-residual and no-residual patients, VEGFR2high was more common 
in long-term samples than in control (no-residual, 75.0% vs 54.2%, p=0.033; and with-
residual, 85.7% vs 28.6% p=0.006, Figure 3,d-g). However, the difference in VEGFAhigh was 
not statistically significant, among both no-residual and with-residual subgroups. 
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VEGFA and VEGFR2 expressions and PFS duration 
To investigate the changes of biomarkers by PFS duration, we analyzed the VEGFA and 
VEGFR2 expression in 4 subgroups: PFS ≥ 120 moths (10+year), PFS=60-119 months (5-
10 years), PFS= 13-36 months (1-3 years), and PFS= 6-12 months. There was still no 
difference in age, FIGO stage and tumor residual among the 4 subgroups. VEGFR2high was 
seen most frequently (91.3%) in PFS 10+years subgroup. The highest median IRS of 9 was 
also found in PFS 10+years patients, and the lowest score of 6 was in group of PFS 1-3 years 
(p=0.001). VEGFR2 expression stayed stable in patients with PFS of less than 3 years (no 
difference between 6-12months and 1-3 years groups, P=0.211). However, VEGFR2 
expression significantly increased in groups of 5-10 years and 10+years (p<0.001). On the 
contrary, with a stable median IRS of 8 in all subgroups, VEGFA expression was found to be 















In our study, we found VEGFR2 overexpression significantly associated with long-term PFS 
in primary HGSOC patients, independent of age, FIGO stage and tumor residual mass. The 
correlation between VEGFA expression and long-term survival was not significant, despite 
VEGFA and VEGFR2 expressions were positively correlated in our analyses.  
 
VEGF has been considered as a promising target for anticancer therapeutics. The most 
common approaches to inhibit VEGF have been VEGFR-targeted or VEGFA-targeted 
molecules, which have been applied on both primary and recurrent ovarian cancers [19, 26-
28]. Three phase III randomized trials showed a median extension of 4-6 months in PFS 
after anti-VEGFA (Bevacizumab) or anti-VEGFR treatments (Pazopanib) in primary ovarian 
cancers [26, 29, 30]. In GOG 0218 trial (NCT00262847), chemotherapy plus Bevacizumab 
failed to achieve significant improvement on the overall survival compared with 
chemotherapy alone. However, according to the median PFS of 15 months and the follow-
up time of 3 years in these studies, long-term survivors with PFS of 5+ years were rarely 
included. In our study, VEGFR2 overexpression in long-term survivors of HGSOC was the 
first time reported. Nevertheless, this finding should be further verified in mechanism studies.   
 
One of strengths in our study is the well-selected population. In previous reports, patients 
were not matched by established prognostic-factors such as stage, residual status and age. 
When including these factors into multivariate analyses, the case numbers for HGSOC 
patients were very small [15, 16, 20] [27, 28, 32]. And the prognostic value of VEGFA or 
VEGFR2 were much reduced, when adjusted by stage, grade, histology and residual status 
[11, 15-17]. In addition, earlier researches mostly analyzed a mix population of both platinum-
resistant and platinum-sensitive patients [9-11, 16, 17, 19, 25, 31]. Due to the distinct biology 
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and different prognosis between platinum-resistant and platinum sensitive OC [1-2], in our 
study only platinum-sensitive patients were included, and all of them are diagnosed as 
HGSOC in advanced stages. Particularly, we only included patients with advanced stage to 
avoid bias, as those with early stage usually had much better prognosis [5]. And the 
influences of established prognostic factors (age and residual disease) were also eliminated 
through the matching process. Thus, we revealed an independent impact of VEGFR2 on 
good prognosis. 
 
Besides appropriate patient-selection, long-term follow-up also should be stressed when 
evaluating the role of VEGFA/VEGFR2. One study demonstrated the correlation between 
VEGFA and response to chemotherapy was only found within 6 months after treatment. 
However, the correlation was not significant within 12 months after chemotherapy [18]. A 
randomized clinical trial showed a similar result that VEGFA inversely impacted on PFS 
according to the length of  treatment [33]. High expression of VEGFA predicted shorter PFS 
in 2-year treated women but correlated with longer PFS in 5-years treated patients. Similar 
with these results, we also found that VEGFR2 expression increased significantly among 
long-term survivors, while remaining a stable level in patients with PFS of 6months-3years. 
According to our results, long-term follow-up should be considered when accessing the value 
of VEGFR2 in HGSOC patients. 
 
We also included the present largest sample-size of long-term HGSOC survivors and 
matched controls, highlighted as another strength of this study. Since 5+ year PFS is rare in 
patients with advanced HGSOC, our 124 patients are the largest homogeneous population 
to investigate VEGFR2 and prolonged outcomes. Particularly, centers in our tumor bank 
consortium are all high-volume centers of ovarian cancer, providing high quality of the tumor 
debulking and standardized protocols of sample collection.  
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Similar to our findings, Zhang et al. reported a higher protein levels of VEGFR2 in control 
tissue compared with human squamous-cell carcinomas, and upregulated VEGFR2 
expression when treating tumor-associated endothelial cells by anti-VEGFA monoclonal 
antibody bevacizumab [34]. The inhibition of tumor angiogenesis was mediated by blockage 
of VEGF that induced up-regulation of VEGFR2 through the JNK/c-Jun pathway and 
ubiquitin-proteasome system [34]. This finding might help to explain why VEGFR2 
overexpression was significantly more frequent in long-term survivors in our study. The long-
term values of anti-VEGFR or anti-VEGFR2 treatments for HGSOC patients may need 
further validation. 
  
The overexpressed VEGFR2 in our “long-term survivors” might also result from the patient 
selection, which may include more patients with BRCA1/2 mutations that are strongly related 
to improved prognosis [35-37]. Our previous study demonstrated that HGSOC patients with 
somatic BRCA1/2 mutations had higher protein level of VEGF, and their prognosis were 
better [38]. BRCA mutation carriers were found with higher levels of VEGF mRNA (p= 0.04) 
than the non-carriers in a breast cancer study [39]. Further, an ovarian cancer study revealed 
an overexpressed VEGF-dependent gene signature (VDGs) in BRCA mutation carriers [40]. 
VEGF can be down-regulated by Caveolin-1, which can be inhibited by dysfunctional BRCA1 
in HGSOC, resulting an increased expression of VEGF [41]. However, there were no 
available samples to analyze BRCA1/2 mutation in our study. BRCA1/2 mutation should be 
assessed together with VEGF expression in further investigation on HGSOC survivors.  
 
VEGFR2 binds different members of the VEGF family and affect systems other than 
angiogenesis. VEGFC and VEGFD can also activate VEGFR2 to assemble lymphatic 
vessels and capillaries affecting not only primary tumor growth but also lymphatic vessel 
functionality and tumor cell metastatic spread [42-44]. In our study, VEGFR2 and VEGFA 
expression were significantly correlated, but only VEGFR2 overexpression has been found 
 18 
in long-term survivors, indicating other mechanisms might also be involved in VEGFR2 
activation. Nevertheless, we only tested VEGFA and VEGFR2 expression as they were major 
regulation markers of angiogenesis, which was one our limitations. Further investigation and 
validation on this signaling pathway are therefore needed.  
 
The study has some limitations. The sample size was relatively small, and information of 
BRCA status and VEGFC/VEGFD staining were not available. Besides, patients experienced 
anti-VEGF/VEGFR treatments were not included in the study, and the control group were all 
from single center (Charité Medical University of Berlin).  
 
In conclusion, VEGFR2 overexpression was found to independently correlate with long-term 
PFS for patient with primary advanced HGSOC. Further clinical trials and basic studies 
should investigate the long-term value of anti-VEGF therapies. However, our findings may 
still provide a new insight into understanding tumor pathogenesis of ovarian cancer patients 
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Notes: In analysis of difference between two groups, Mann-Whitney U test was used for continuous variables and Chi-













  Mean ± SD   
Age 124 56.6±10.0 57.1±10.2 0.841 






124   0.260 
  53 (85.5) 57 (91.9) 
 9   (14.5) 5   ( 8.1 ) 
Tumor residual 124   1.0 
No  48 (77.4) 48 (77.4)  
Yes  14 (22.6) 14 (22.6)  
Ascites 115   0.011 
No 
≤500ml 
 6   (10.7)                    
28 (50.0) 
19 (32.2)                    
27 (45.8) 
 
＞500ml  22 (39.3) 13 (22.0)  
CA125 before surgery 105   0.318 
≤500 U/ml  21 (38.9) 22 (48.9)  
＞500 U/ml  33 (61.1) 33 (51.1)  
Lymph node metastasis 124   0.340 
NX  4   ( 6.5 ) 9   (14.5)  
N0  17 (27.4) 16 (25.8)  
N1  41 (66.1) 37 (59.7)  
Neoadjuvant chemotherapy 108   0.558 
No  55(98.2) 49(94.2)  
Yes  1  ( 1.8 ) 3  ( 5.8 )  
Chemotherapy  124   0.001 
Taxol+Carboplatin  56 (90.3) 40 (64.5)  
Carboplatin or Cisplatin  0   ( 0 ) 2  ( 3.2 )  
Other platinum-based therapy  6  ( 9.7 ) 20 (32.3)  
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Table 2. Difference in VEGFA and VEGFR2 expressions between long-term survivors and 
control [45]. 





P* adjusted P a 
   N (%)    
VEGF A 124     
Low  22 (35.5) 13 (21.0) 0.073  
High   40 (64.5) 49 (79.0)   
VEGF R2 124   0.001 0.005 
Low   32 (48.4) 14 (22.6)   
      High   30 (51.6) 48 (77.4)   
VEGFA+VEGFR2 124     
Both low   18 (29.0) 4 ( 6.5 ) 0.003  
     Both high   26 (42.0) 39 (62.9)   
      Otherb   18 (29.0) 19 (30.6)   
Notes: Chi-Square test was used for categorical variables. Significant difference: P<0.05.  
* Difference between control and long-term groups.  
a. P-value adjusted by FIGO stage and VEGFA expression in logistic regression model.  

















Figure 2. VEGFA and VEGFR2 expression by Immunohistochemistry: weak expressions of 
VEGFA (2a) and VEGFR2 (2e) in tumor cells; strong expressions of VEGFA (2b) and 
VEGFR2 (2f) in tumor cells with weak background staining in stroma cells; and IRS 









Figure 3. Difference in VEGFA and VEGFR2 expressions between long-term and the control 
groups: VEGFA (a) and VEGFR2 (b) expression and their co-expression (c) between two 
groups in all patients (n=124); difference in VEGFA (d) and VEGFR2 (e) expressions 
between two groups in no-residual patients (n=96); and difference in VEGFA (f) and VEGFR2 




















Figure 4. Correlation between VEGFA/VEGFR2 expressions and PFS: IRS of 
VEGFA (4a) and VEGFR2 (4b), and high expression of VEGFA (4c) and VEGFR2 
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